Immunosuppressive drugs for kidney transplantation, N Engl J Med, vol.351, pp.2715-2744, 2004. ,
The long-term course of cyclosporineassociated chronic nephropathy, Kidney Int, vol.33, pp.590-600, 1988. ,
Chronic renal failure after transplantation of a nonrenal organ, N Engl J Med, vol.349, pp.931-971, 2003. ,
Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage ,
, Transpl Int, vol.23, pp.364-73, 2010.
Regulatory T Cells in kidney disease and transplantation, Kidney Int, vol.90, pp.502-516, 2016. ,
Calcineurin inhibitor-sparing regimens based on mycophenolate acid after kidney transplantation, Transpl Int, vol.28, pp.928-931, 2015. ,
Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function, Am J Nephrol, vol.24, pp.379-86, 2004. ,
,
, Mycophenolate mofetil substitution for cyclosporine in renal transplant recipients with chronic progressive allograft dysfunction : the « creeping creatinine study, Transplantation, vol.79, pp.466-75, 2005.
,
Long-term impact of cyclosporin reduction with MMF treatment in chronic allograft dysfunction : REFERENCE study 3-year follow up, J Transplant, 2010. ,
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study, Transplantation, vol.74, pp.1725-1759, 2002. ,
, 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits
, Nephrol Dial Transplant, vol.25, pp.3096-106, 2010.
Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation, Transplant Rev, vol.27, pp.97-107, 2013. ,
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients : a randomized phase II study, Clin J Am Soc Nephrol, vol.6, pp.430-439, 2011. ,
Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-years results from the long-term extension of a phase II study, Transplant Int, vol.25, pp.1059-64, 2012. ,
Avoidance of cyclosporine in renal transplantation : effects of daclizumab, mycophenolate mofetil, and steroids, J Am Soc Nephrol, vol.11, pp.1903-1912, 2000. ,
Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil, Transplant Int, vol.21, pp.637-682, 2008. ,
Cyclosporine sparing with mycophenolate mofetil daclizumab and corticosteroids in renal allograft recipients : the CAESAR study, Am J Transplant, vol.7, pp.560-70, 2007. ,
,
, N Engl J Med, vol.35, pp.2562-75, 2007.
De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years, Am J Transplant, vol.4, pp.1776-85, 2004. ,
The ORION study: comparison of two sirolimus based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients, Am J Transplant, vol.11, pp.1633-1677, 2011. ,
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial, Lancet, vol.377, pp.837-884, 2011. ,
Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation : concept study, Am J Transplant, 2009. ,
A phase III study of belatacept versus cyclosphorine in kidney transplants from extended criteria donors (BENEFIT-EXT study), Am J Transplant, vol.10, pp.547-57, 2010. ,
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients, Am J Transplant, vol.12, pp.210-217, 2012. ,
Immunological risks of minimization strategies, Transplant Int, vol.28, pp.901-911, 2015. ,
Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis, Transplantation, vol.87, pp.591-605, 2009. ,
Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation, J Am Soc Nephrol, vol.22, pp.2107-2125, 2011. ,
Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta-Analysis ,
, Am J Transplant, vol.16, pp.2117-2155, 2016.
Recent advances in renal transplantation: antibody-mediated rejection takes center stage, Rep, vol.12, pp.7-51, 2015. ,
Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes, Transplantation, vol.91, pp.1103-1112, 2011. ,
Posttranspantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome, Transplantation, vol.75, pp.1034-1074, 2003. ,
Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts, Transplantation, vol.87, pp.1505-1518, 2009. ,
Prediction kidney graft failure by HLA antibodies: a prospective trial, Am J Transplant, vol.4, pp.438-481, 2004. ,
HLA specific antibodies developed in the first year posttransplant are predicitve of chronic rejection and renal graft loss, Transplantation, vol.88, pp.568-74, 2009. ,
Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection, Transplantation, vol.97, pp.534-574, 2014. ,
Influence of de novo donor-specific antibody on early renal allograft function recovery, Ren Fail, vol.37, pp.462-470, 2015. ,
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure, Am J Transplant, vol.9, pp.2520-2551, 2009. ,
IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury ,
, J Am Soc Nephrol, vol.27, pp.293-304, 2016.
Complement-binding anti-HLA antibodies and kidney-allograft survival, N Engl J Med, vol.369, pp.1215-1241, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-02325503
Non complement-binding de novo donor-specific anti HLA antibodies and kidney allograft survival, J Am Soc Nephrol, vol.27, pp.615-640, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01953712
Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts, Am J Transplant, vol.7, pp.576-85, 2007. ,
Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4D staining, Am J Transplant, vol.9, pp.2312-2335, 2009. ,
Antibody-mediated renal allograft rejection : diagnosis and pathogenesis, J Am Soc Nephrol, vol.18, pp.1046-56, 2007. ,
Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies, Am J Transplant, vol.9, pp.256-70, 2009. ,
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant, Am J Transplant, vol.12, pp.1157-67, 2012. ,
De novo donor specific human leukocyte antigen antibodies in nonsensitized kidney transplant recipients after T cell-mediated rejection, Transplantation, vol.99, pp.965-72, 2015. ,
Antibody-mediated vascular rejection of kidney allografts: a population-based study, Lancet, vol.381, pp.313-322, 2013. ,
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation, J Am Soc Nephrol, vol.22, pp.975-83, 2011. ,
Evolution of donor specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors, Clin Transplant, vol.28, pp.1054-60, 2014. ,
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation, Am J Transplant, vol.12, pp.1192-1200, 2012. ,
Identifying specific causes of kidney allograft loss, Am J Transplant, vol.9, pp.527-562, 2009. ,
Therapeutic drug monitoring of cyclosporine and tacrolimus, Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus, vol.31, pp.309-325, 1998. ,
Therapeutic Monitoring of Calcineurin Inhibitors for the Nephrologist, Clin J Am Soc Nephrol, vol.2, pp.374-384, 2007. ,
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation, Transplantation, vol.95, pp.19-47, 2013. ,
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts, Transplantation, vol.95, pp.410-417, 2013. ,
Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents, Tranplantation, vol.97, pp.294-300, 2014. ,
De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients, Am J Transplant, vol.13, pp.1541-1549, 2013. ,
Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies, J Am Soc Nephrol, vol.26, pp.966-975, 2015. ,
Acute humoral rejection in hepatitis Cinfected renal transplant recipients receiving entiviral therapy, Am J Transplant, vol.3, pp.74-82, 2003. ,
The influence of Immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients, Transplantation, vol.100, pp.39-53, 2016. ,
Liquid Chromatography/Mass Spectrometry For Therapeutic Drug Monitoring of Immunosuppressants, Analytica Chimica Acta, vol.492, pp.133-178, 2003. ,
, Tableau 2 (suite) Total (n=247) Non Minimisés Minimisés Néphropathie initiale 0, p.27
, Glomérulonephrite chronique (hors vascularite) 63 (25,5%) 21 (25,6%) 42 (25,5%)
, Type de donneur 0, p.8
, Décédé-critères élargis, vol.63, p.9
,
, HTA : Hypertension artérielle ; AVC : Accident vasculaire cérébral ; AOMI : Artériopathie Oblitérante des Membres inférieurs
, VIH : Virus d'immunodéficience humaine ; BPCO : Bronchopneumopathie chronique obstructive ; SAL : Sérum anti-lymphocytaire